Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||cholangiocarcinoma||not applicable||Cisplatin + Gemcitabine + Silmitasertib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the protein kinase CK2 inhibitor, Silmitasertib (CX-4945), in combination with Platinol (cisplatin) and Gemzar (gemcitabine), inhibited tumor growth and increased survival of cholangiocarcinoma cell line xenograft models, to a greater extent than either compound alone (PMID: 30316146).||30316146|